Alembic Pharmaceuticals share price rose in the opening trade on June 8 after the company signed a shareholders' agreement to invest in a newly incorporated Canadian entity, Canada Inc., aimed at ...

AI Quick Read Alembic Pharmaceuticals Ltd is expanding its branded speciality drugs portfolio in the US as part of a ‘twin engine play’ to boost growth in the market as generic pricing pressure ...

Vadodara: Alembic Pharmaceuticals is taking a direct route into Europe, setting up a new entity in Germany to strengthen its international reach and tap into fresh growth opportunities. Establishes ...

Vadodara: Alembic Pharmaceuticals is adding another regulated-market approval to its portfolio, reinforcing its presence in the US generics space with a key oncology and autoimmune therapy product.

BEDMINSTER, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics is pleased to announce the U.S. availability of Pivya® (pivmecillinam) tablets, 185mg, an oral prescription antibiotic. Pivya ...

Alembic Pharmaceuticals Ltd on Monday said it has received tentative approval from the US health regulator for its Bosutinib tablets used in the treatment of certain types of cancer. The tentative ...

Drugmaker Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Travoprost Ophthalmic Solution ...

Causal artificial intelligence startup Alembic Technologies Inc. said today it has raised $145 million in a Series B growth round that increases its valuation almost 16-fold. It’s using a big chunk of ...

Alembic, a startup that offers AI-powered data analytics for marketers, said it has raised $145 million in a fundraising round that values the company at $645 million. Alembic’s software is designed ...

Alembic Technologies has raised $145 million in Series B and growth funding at a valuation 15 times higher than its previous round, betting that the next competitive advantage in artificial ...